NET ASSET VALUE – 31 July 2024

MARKN.
On the 31 July 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,327 million and NAV per share was SEK 55.43. 
Allocation of NAVShare of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV





     
Product Development    
Prokarium42%4836.1911.2%
Xspray Pharma18%3003.856.9%
Empros Pharma79%2042.624.7%
KAHR Medical31%2022.594.7%
Atrogi34%1541.973.6%
Microbiotica11%1381.763.2%
Lipum57%1351.733.1%
Geneos Therapeutics12%1031.322.4%
Xintela56%1021.302.4%
Mendus24%971.242.2%
Toleranzia58%680.871.6%
EpiEndo Pharmaceuticals9%580.741.3%
Synerkine Pharma43%530.681.2%
AnaCardio19%520.661.2%
Egetis Therapeutics2%420.531.0%
Buzzard Pharmaceuticals14%290.370.7%
Vitara Biomedical5%290.370.7%
Sixera Pharma23%260.330.6%
Alder Therapeutics21%170.220.4%
Amarna Therapeutics60%120.150.3%
Strike Pharma16%90.110.2%
Total 2,31229.6253.4%
    
Commercial Growth   
NorthX Biologics92%1892.424.4%
Symcel31%1692.163.9%
Nanologica39%951.222.2%
A3P Biomedical8%750.961.7%
Chromafora31%730.931.7%
Provell Pharmaceuticals72%700.901.6%
Frontier Biosolutions2%190.250.4%
Bohus Biotech45%170.210.4%
Total 7079.0616.3%
    
Limited Partnerships, total 831.061.9%
    
Assets related to portfolio companies 4045.179.3%
Other assets and liabilities 82110.5219.0%
    
NAV 4,32755.43100.0%
  

 
* indirect shares in Provell Pharmaceuticals
 
   

Datum 2024-08-02, kl 08:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet